Quick Answer
MBX Biosciences, Inc. reported Cash and Equivalents of $75.29 million for fiscal year 2025.
MBX Biosciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $75.29M | +52.6% |
| 2024 | $49.35M | +61.7% |
| 2023 | $30.52M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $223.12M | +67.9% | +460.9% |
| June 30, 2025 | $39.78M | — | +33.0% |
| March 31, 2025 | $29.90M | — | -39.4% |
| December 31, 2024 | $49.35M | +61.7% | -62.9% |
| September 30, 2024 | $132.87M | — | +335.3% |
| December 31, 2023 | $30.52M | — | — |
- MBX Biosciences, Inc. showed an increase of +52.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, MBX Biosciences, Inc.’s cash and equivalents has grown by 146.7% (from $30.52 million to $75.29 million).
- The most recent figure is from MBX Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: